Thomas DiRaimondo - 01 Jan 2024 Form 3 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Chief Scientific Officer
Signature
/s/ Maria Dobek, Attorney-in-Fact
Issuer symbol
JANX
Transactions as of
01 Jan 2024
Net transactions value
$0
Form type
3
Filing time
03 Jan 2024, 16:45:23 UTC
Next filing
03 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding JANX Common Stock 101,532 01 Jan 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding JANX Stock option (right to buy) 01 Jan 2024 Common Stock 153,720 $0.5940 Direct F1
holding JANX Stock option (right to buy) 01 Jan 2024 Common Stock 140,910 $4.21 Direct F2
holding JANX Stock option (right to buy) 01 Jan 2024 Common Stock 256,200 $10.59 Direct F3
holding JANX Stock option (right to buy) 01 Jan 2024 Common Stock 23,970 $20.24 Direct F4
holding JANX Stock option (right to buy) 01 Jan 2024 Common Stock 70,000 $14.02 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vested on June 30, 2021 and the balance of the shares vest in equal monthly installments thereafter over a three year period. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
F2 25% of the shares subject to the option vested on March 10, 2022 and the balance of the shares vest in equal monthly installments thereafter over a three year period. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
F3 25% of the shares subject to the option vested on May 14, 2022 and the balance of the shares vest in equal monthly installments thereafter over a three year period. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
F4 25% of the shares subject to the option vested on January 1, 2023 and the balance of the shares vest in equal monthly installments thereafter over a three year period.
F5 25% of the shares subject to the option vested on January 1, 2024 and the balance of the shares vest in equal monthly installments thereafter over a three year period.